. 2023 Jan 24;2023:3678327. doi: 10.1155/2023/3678327

Table 2.

Stratification analysis between METTL1 genotypes and glioma risk.

Variables	rs2291617 (cases/controls)		AOR (95% CI)^a	P ^a	rs10877012 (cases/controls)		AOR (95% CI)^a	P ^a	Risk genotypes^b (cases/controls)		AOR (95% CI)^a	P ^a
Variables	GG/GT	TT	AOR (95% CI)^a	P ^a	TT/TG	GG	AOR (95% CI)^a	P ^a	0	1–3	AOR (95% CI)^a	P ^a
Age, month
<60	109/153	24/21	1.60 (0.85-3.03)	0.145	111/155	22/19	1.61 (0.83-3.12)	0.156	109/153	24/21	1.60 (0.85-3.03)	0.145
≥60	147/177	32/29	1.32 (0.76-2.28)	0.323	146/177	33/29	1.37 (0.80-2.37)	0.256	145/177	34/29	1.42 (0.83-2.44)	0.205
Gender
Females	119/140	26/24	1.23 (0.67-2.26)	0.513	119/141	26/23	1.29 (0.70-2.39)	0.420	118/140	27/24	1.29 (0.70-2.36)	0.417
Males	137/190	30/26	1.61 (0.91-2.85)	0.102	138/191	29/25	1.60 (0.90-2.85)	0.113	136/190	31/26	1.67 (0.95-2.94)	0.076
Subtypes
Astrocytic tumors	173/330	39/50	1.47 (0.93-2.35)	0.101	173/332	39/48	1.53 (0.96-2.44)	0.076	171/330	41/50	1.56 (0.99-2.47)	0.057
Ependymoma	51/330	10/50	1.42 (0.66-3.03)	0.366	52/332	9/48	1.35 (0.61-2.96)	0.461	51/330	10/50	1.42 (0.66-3.03)	0.366
Neuronal and mixed	20/330	5/50	1.68 (0.60-4.70)	0.325	20/332	5/48	1.75 (0.62-4.92)	0.287	20/330	5/50	1.68 (0.60-4.70)	0.325
Embryonal tumors	10/330	2/50	0.93 (0.19-4.71)	0.934	10/332	2/48	0.95 (0.19-4.83)	0.954	10/330	2/50	0.93 (0.19-4.71)	0.934
Clinical stages
I + II	183/330	41/50	1.46 (0.93-2.29)	0.103	186/332	38/48	1.39 (0.87-2.20)	0.169	183/330	41/50	1.46 (0.93-2.29)	0.103
III + IV	72/330	15/50	1.32 (0.70-2.50)	0.388	70/332	17/48	1.61 (0.87-2.97)	0.131	70/330	17/50	1.54 (0.83-2.84)	0.168

AOR: adjusted odds ratio; CI: confidence interval. ^aAdjusted for age and gender, omitting the corresponding stratify factor. ^bRisk genotypes were carriers with rs2291617 TT, rs10877013 CC, and rs10877012 GG genotypes.